Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

NCT04281498 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Accelerated/Blast-phase Myeloproliferative Neoplasm
Chronic-phase Myelofibrosis
IDH2 Mutation

Interventions

DRUG: Ruxolitinib
DRUG: Enasidenib

Sponsor

John Mascarenhas

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]